Clinical Trial Update: Multicenter Phase II of CD26 Using Sitagliptin for Engraftment After UBC Transplant [Phase 2]

View source ↗

Summary

Phase II multicenter trial evaluating CD26 inhibition with sitagliptin for engraftment after umbilical cord blood transplant in hematologic malignancies; study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Hematopoietic Myelodysplasia
• Leukemia Myelogenous Chronic
• Lymphoid Leukemia
• Lymphoma Non-hodgkin

Drugs mentioned

• Sitagliptin (sitagliptin)

Snippet

Sponsor: Sherif S. Farag | Conditions: Acute Myeloid Leukemia, Acute Lymphoid Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2019-01-08